Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.89 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.89 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.89 |
| ▸ | NPC1 | O15118 | 9/20 | 0.75 |
| ▸ | RAB9A | P51151 | 9/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.75 |
| ▸ | HTT | P42858 | 2/20 | 0.70 |
| ▸ | MAPT | P10636 | 6/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.66 |
| ▸ | TP53 | P04637 | 2/20 | 0.65 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.65 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.65 |
| ▸ | RELA | Q04206 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.63 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.63 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30739608 | 1.00 | LMNA (1.00) | LMNAMEN1KMT2ATDP1NPC1 | |
| SCHEMBL4363732 | 0.89 | MEN1 (0.89) | LMNAMEN1KMT2ATDP1NPC1 | |
| SCHEMBL30799144 | 0.86 | MEN1 (0.83) | LMNAMEN1KMT2ATDP1NPC1 | |
| SCHEMBL30739758 | 0.86 | LMNA (0.75) | LMNAMEN1KMT2ATDP1NPC1 | |
| SCHEMBL6300571 | 0.86 | KMT2A (0.83) | LMNAMEN1KMT2ATDP1NPC1 | |
| SCHEMBL14825062 | 0.86 | NPC1 (1.00) | LMNAMEN1KMT2ATDP1NPC1 | |
| SCHEMBL679040 | 0.86 | MEN1 (0.83) | LMNAMEN1KMT2ATDP1NPC1 | |
| SCHEMBL4825016 | 0.86 | KMT2A (0.83) | LMNAMEN1KMT2ATDP1NPC1 | |
| SCHEMBL17115776 | 0.86 | NPC1 (1.00) | LMNAMEN1KMT2ATDP1NPC1 | |
| SCHEMBL13581604 | 0.86 | MEN1 (0.83) | LMNAMEN1KMT2ATDP1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3481394-A1 | THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER | Janssen Pharmaceutica N.V. (BE) | 2019-05-15 | — | — | EP | claimed |
| WO-2018009694-A1 | THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-11 | — | — | WO | claimed |
| EP-3284738-B1 | 5-AROMATIC ALKYNYL SUBSTITUTED BENZAMIDE COMPOUND AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | SHANGHAI INST MATERIA MEDICA CAS (CN) | 2020-11-25 | — | — | EP | disclosed |
| EP-3500259-A1 | THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER | Janssen Pharmaceutica NV (BE) | 2019-06-26 | — | — | EP | disclosed |
| EP-3481394-A1 | THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER | Janssen Pharmaceutica N.V. (BE) | 2019-05-15 | — | — | EP | disclosed |
| WO-2018037342-A1 | THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2018-03-01 | — | — | WO | disclosed |
| WO-2018009694-A1 | THIOHYDANTOIN ANDROGEN RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CANCER | JANSSEN PHARMACEUTICA NV (BE) | 2018-01-11 | — | — | WO | disclosed |
| US-9056284-B2 | Chlorine resistant amides, polyamides, and membranes made from the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE INTERIOR (US) | 2015-06-16 | — | — | US | disclosed |
| US-9056284-B2 | Chlorine resistant amides, polyamides, and membranes made from the same | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE INTERIOR (US) | 2015-06-16 | — | — | US | disclosed |
| US-20140042082-A1 | CHLORINE RESISTANT AMIDES, POLYAMIDES, AND MEMBRANES MADE FROM THE SAME | THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE INTERIOR | 2014-02-13 | — | — | US | disclosed |
| US-20140042082-A1 | CHLORINE RESISTANT AMIDES, POLYAMIDES, AND MEMBRANES MADE FROM THE SAME | THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE INTERIOR | 2014-02-13 | — | — | US | disclosed |
| US-6897316-B2 | Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents | CHINA MEDICAL UNIVERSITY (TW) | 2005-05-24 | — | — | US | disclosed |
| US-20050032832-A1 | Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents | CHINA MEDICAL UNIVERSITY (TW) | 2005-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050032832-A1 | Substituted 2-phenyl-4-quinolone-3-carboxylic acid compounds and their use as antitumor agents | TP53, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CHUK | LMNA 3189/4885MEN1 3877/4885KMT2A 780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.